SPONSOR
Shanghai Chest Hospital
Total Trials
10
Recruiting
10
Phases
Phase 2, Phase 3
Conditions studied: Ground-Glass OpacityLimited-stage Small Cell Lung Cancer (LS-SCLC)ChemoradiotherapyInduction TherapyConsolidation ImmunotherapyNon Small Cell Lung CancerEsophageal CancerSmall-cell Lung CancerSmall Cell Lung Cancer, Combined TypeSmall Cell Lung Carcinoma
Shanghai Chest Hospital is a clinical research sponsor with 10 registered studies on ClinicalTrials.gov, of which 10 are actively recruiting participants. Research covers conditions including Ground-Glass Opacity, Limited-stage Small Cell Lung Cancer (LS-SCLC), Chemoradiotherapy, Induction Therapy.
The trial portfolio spans Phase 2, Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Shanghai Chest Hospital
How many clinical trials has Shanghai Chest Hospital sponsored?
ClinicalMetric currently tracks 10 clinical trials sponsored by Shanghai Chest Hospital, of which 10 are actively recruiting participants. These trials cover conditions including Ground-Glass Opacity, Limited-stage Small Cell Lung Cancer (LS-SCLC), Chemoradiotherapy. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Shanghai Chest Hospital research focus on?
Shanghai Chest Hospital clinical trials span Ground-Glass Opacity, Limited-stage Small Cell Lung Cancer (LS-SCLC), Chemoradiotherapy, Induction Therapy, Consolidation Immunotherapy, and additional conditions. The research pipeline includes Phase 2, Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Shanghai Chest Hospital clinical trial?
To participate in a Shanghai Chest Hospital trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Shanghai Chest Hospital trials with current recruitment status updated daily.
Clinical Trials by Shanghai Chest Hospital
NCT06848881
Recruiting
Cryoablation vs Thoracoscopic Surgery for GGN
Ground-Glass Opacity
NCT07091305 Phase 2
Recruiting
A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy
Limited-stage Small Cell Lung Cancer (LS-SCLC)
NCT06730503
Recruiting
Glycoprotein in Immunotherapy Response and Efficacy Prediction of Lung Cancer
Non Small Cell Lung Cancer
NCT06385730 Phase 2
Recruiting
Neoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS)
Esophageal Cancer
NCT04135664 Phase 3
Recruiting
Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma
Esophageal Cancer
NCT05945745
Recruiting
Molecular Analysis and Treatment Options of SCLC
Small-cell Lung Cancer
NCT05798845 Phase 2
Recruiting
The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer
NSCLC
NCT07058519 Phase 2
Recruiting
A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC
Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)
NCT07549061 Phase 2
Recruiting
Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC
NSCLC (Advanced Non-small Cell Lung Cancer)
NCT06698965 Phase 2
Recruiting
Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin
Lung Cancer, Small Cell
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology